CURN.SW

CURATIS N AG

CURN.SW, Switzerland

Curatis Holding AG engages in the acquisition, development, and commercialization of medicines for the prevention, diagnosis, and treatment of rare and specialty care diseases. It offers its products in the areas of antiplatelet, metastatic hormone receptor-positive breast cancer, anti-arrhythmic, nasal oil, wilson's disease, cyanide poisoning, digoxin toxicity, antihypotensive, bladder pain syndrome/intersticial cystitis, antibioticum, diagnostic ophthalmology, antiviral, ophtalmic/ antibioticum, gentamycin collagen sponge, benign prostatic hyperplasia, immunomodulator, epilepsy and essential tremor, thyreostatic, hereditary tyrosinemia type 1, gastroenterologic, immunomodulator, thyreostatic, tranquilizer, helicobacter pylori test, phosphate binder, special nutrition for dialysis patients, dermato corticosteroid, lead and mercury poisoning, corticostimulin, anti-fog agent, chorea associated with huntington's disease, and antiepileptic. The company also develops C-PTBE-01, which is in Phase IIb clinical trial for the treatment of peritumoral brain edema in pediatric patients; C-AM-01 that is in Phase IIa clinical trial for the prevention of severe migraine with aura; C-MOH-01, which is in Phase IIa clinical trial for the treatment and prevention of medication overuse headache; and KIN001 that is in Phase I clinical trial for the treatment of rare inflammatory and fibrotic diseases. The company is based in Liestal, Switzerland.

https://curatis.com

Stock Price

CHF0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
CURN.SW
stock
CURN.SW

The recent 28% gain must have brightened Top Key Executive Gunter Graubach's week, Curatis Holding AG's (VTX:CURN) most bullish insider Yahoo Finance

Read more →

Finn Analysis

(Last Updated 2025-06-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

1.37

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-2.61 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-2.14 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-20.12 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very High

0.22

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 0.00% of the total shares of CURATIS N AG

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2022-06-30

EPS Actual

0

EPS Estimate

0

EPS Difference

0

Surprise Percent

0%

Investing Fit Scorecard

(Last Updated 2025-06-30)

Deep Value
Potential Value Candidate(4)
Defensive
Moderately Defensive(5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(3)
Growth
Weak Growth Prospect(1.5)
Momentum
No Momentum(2)
Net Net
Not Undervalued (Net-Net)(1)
Quality
Low Quality Business(2.5)
Value
Fair Value(4.5)

Income Statement

(Last Updated 2025-06-30)

Revenue

CHF 0

Cost Of Revenue

CHF 0

Gross Profit

CHF 0

Operating Expenses

CHF 0

Operating Income

CHF 0

Interest Expense

CHF 0

Pretax Income

CHF 0

Net Income

CHF 0

Income Tax Expense

CHF 0

EBITDA

CHF 0

Total Other Income Expense Net

CHF 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-06-30)

Cash

CHF 0

Short Term Investments

CHF 0

Receivables

CHF 0

Inventories

CHF 0

Total Current Assets

CHF 0

Property Plant Equipment

CHF 0

Total Assets

CHF 0

Payables

CHF 0

Short Term Debt

CHF 0

Long Term Debt

CHF 0

Total Liabilities

CHF 0

Equity

CHF 0

Trend

Cash Flow

(Last Updated 2025-06-30)

Net Income

CHF 0

Depreciation

CHF 0

Change In Working Capital

CHF 0

Cash From Operations

CHF 0

Capital Expenditures

CHF 0

Cash From Investing

CHF 0

Cash From Financing

CHF 0

Net Change In Cash

CHF 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.